Awaiting potential/possible news on PV-10 clinical studies with pharma partner after recent clinical read out, possible ocular news from Univ of Miami, or even some Australian TGA development. Fundamental news will move this stock, TA will come in handy after the fact. Believe it is a decent buy and wait scenario in the .10 to .12 range. Shareholder supportive management, but cash strapped operations. Insider buying past 6 months. A long shot, but rewards for patients and investors could be big.
